GSK Spending Spree Continues With Sosei Heptares Pact
Deal Covers Candidates For IBD
Having just entered into drug discovery partnerships with Surface Oncology and Adrestia, GSK is paying £34m upfront to team up with Sosei Heptares to evaluate treatments for gastrointestinal immune disorders.
